Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
Avivit CahnStephen D WiviottLawrence A LeiterSabina A MurphyErica L GoodrichIlan YanuvAliza RozenbergJohn P H WildingLawrence Alan LeiterDeepak L BhattDarren K McGuireLeon LitwakAdriaan KooyIngrid A M Gause-NilssonMartin FredrikssonAnna Maria LangkildeMarc S SabatineItamar RazPublished in: Diabetes, obesity & metabolism (2020)
The effects of dapagliflozin on cardiorenal outcomes were generally consistent regardless of baseline GLA, with consistent benefits regardless of baseline metformin use. The potential clinical benefit of combining sodium-glucose co-transporter-2 inhibitors with GLP-1 RAs, given some evidence of cardiovascular risk reduction with both classes, should be explored further.